Oragenics, Inc. (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) have announced the signing of a letter of intent (LOI) under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn’s CardioDialysis™ blood purification technology. The technology will be targeted at traumatic brain injury (TBI) and chronic neurodegenerative diseases, according to a press release.
The proposed license would allow Oragenics to combine CardioDialysis with its Phase IIa intranasal neurosteroid candidate ONP-002 in a dual-modality approach that targets inflammation on both sides of the blood-brain barrier. This strategy aims to address the inflammatory processes that contribute to neurological damage in conditions such as TBI, Parkinson’s disease, Alzheimer’s disease, and others.
Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury. The company is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
Sigyn Therapeutics’ CardioDialysis technology is a blood purification system designed to remove a broad spectrum of inflammatory mediators from the bloodstream. By targeting systemic inflammation, the technology may complement Oragenics’ intranasal approach, which delivers therapy directly to the brain. Together, the combination could offer a comprehensive treatment strategy for neurological conditions where inflammation plays a key role.
The LOI marks a strategic move for Oragenics to expand its pipeline beyond its current focus on TBI. The company is committed to developing innovative therapies that address significant unmet medical needs in neurological care. The partnership with Sigyn could accelerate the development of new treatment options for patients suffering from chronic neurodegenerative diseases and acute brain injuries.
This announcement is important for the biotechnology industry as it highlights a novel approach to treating neurological disorders by combining systemic and local anti-inflammatory therapies. If successful, the dual-modality approach could set a new standard for managing inflammation in the brain and body, potentially improving outcomes for millions of patients worldwide. Investors and researchers will be watching closely as Oragenics moves forward with its clinical plans.
For more information about Oragenics, visit the company’s website at oragenics.com. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN. The full press release can be accessed at https://ibn.fm/VD4RO.
